新加坡批准为2-49岁人口接种无针流感疫苗, Singapore approves needle-free flu vaccine for ages 2–49 to boost shots and ease fears.

新加坡批准了无针喷鼻流感疫苗 " FluMist Trivalent " ,用于2至49岁的人,这是该国首个国内流感疫苗。 Singapore has approved FluMist Trivalent, a needle-free nasal spray flu vaccine, for use in individuals aged 2 to 49, marking the first intranasal flu vaccine in the country. 经卫生科学局批准,由AstraZeneca公司制造,它防止甲型和乙型流感菌株,每年推荐一次,特别是针对老年人和慢性病患者。 Approved by the Health Sciences Authority and manufactured by AstraZeneca, it protects against influenza A and B strains and is recommended annually, especially for older adults and those with chronic conditions. 此前在美国和英国批准的疫苗旨在通过消除与针头有关的恐惧,提高疫苗接种率。 The vaccine, previously approved in the U.S. and UK, aims to increase vaccination rates by eliminating needle-related fears. 常见副作用包括流鼻涕、喉咙痛和温和发烧。 Common side effects include runny nose, sore throat, and mild fever. 阿联酋还为2至49岁的健康人推出了类似的甲状腺喷雾流感疫苗FluMist Quadrivalent,对某些高风险群体有限制。 The UAE has also launched a similar nasal spray flu vaccine, FluMist Quadrivalent, for healthy individuals aged 2 to 49, with restrictions for certain high-risk groups. 两国正在扩大获得无针选择的机会,以改善公共卫生和免疫率。 Both countries are expanding access to needle-free options to improve public health and immunization rates.